Because FcγRIIB is expressed on tumor-specific CD8+ T cells (20–23), we posited that sFgl2 may temper the T cell antitumor response by binding FcγRIIB+CD8+ cells to induce apoptosis of FcγRIIB+CD8+ T cells in vivo. The gene discussed is CD8A; the disease is neoplasm.